Global Work

CONRAD is providing supplies of the antiretroviral tenofovir gel for an ongoing Phase IIb clinical trial for HIV prevention in South Africa. The trial is a two-arm, double-blind, randomized, controlled study that compares the effectiveness of a 1% tenofovir gel with a placebo gel. A total of 900 HIV-negative, sexually active women between 18 and 40 years have been enrolled at two clinical research sites, Durban and Vulindlela, located in KwaZulu-Natal, South Africa. 

Identification and development of new microbicides, including development and validation of small animal models for HIV and formulation work are ongoing by investigators, collaborators and contractors in Germany, Northern Ireland and the Dominican Republic.

 In both Thailand and Atlanta, CONRAD is working with the Centers for Disease Control on safety studies focusing on the antiretroviral UC 781 for use as a microbicide.

 While the Phase III trial of cellulose sulfate for HIV prevention - held in Benin, South Africa, Uganda and India - concluded early due to lack of efficacy, the trial helped pave the way for research on new, safe and effective microbicides.

Learn more about our global reach here.